Publications by authors named "B V Klimovich"
Article Synopsis
- Breast cancer is the most prevalent cancer in women, and while immunotherapy has shown promise, many patients, especially those with triple-negative breast cancer, either aren't eligible for current treatments or don't respond effectively.
- A study examined tumor samples from 25 breast cancer patients, revealing high levels of CD276, a potential target for new immunotherapies, especially using a novel antibody called CC-3.
- CC-3 demonstrated significant abilities to activate T cells, promote their growth, and kill tumor cells in lab settings, supporting its potential for further clinical trials in breast cancer patients.
Despite the advances in cancer treatment achieved, for example, by the CD20 antibody rituximab, an urgent medical need remains to optimize the capacity of such antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) that determines therapeutic efficacy. The cytokine IL-15 stimulates proliferation, activation, and cytolytic capacity of NK cells, but broad clinical use is prevented by short half-life, poor accumulation at the tumor site, and severe toxicity due to unspecific immune activation. We here report modified immunocytokines consisting of Fc-optimized CD19 and CD20 antibodies fused to an IL-15 moiety comprising an L45E-E46K double mutation (MIC format).
View Article and Find Full Text PDFArticle Synopsis
- Relapse and graft-versus-host disease (GVHD) are major causes of death after hematopoietic cell transplantation (HCT), and invariant natural killer T (iNKT) cells may help prevent GVHD while fighting malignancies.
- This study aimed to enhance the effectiveness of iNKT cells by creating CD19-CAR-iNKT cells that target lymphoma while maintaining their immune-regulatory properties.
- Results showed that while CD19-CAR-iNKT cells can induce target cell death, they also face exhaustion; however, using checkpoint inhibitors like nivolumab boosted their effectiveness and reduced the risk of GVHD.
Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retroviral element (ERV)-encoded promoters, and the initiation of transcription. Here, we use deep RNA sequencing from cancer cell lines treated with DNA methyltransferase inhibitor (DNMTi) and/or Histone deacetylase inhibitor (HDACi), to assemble a de novo transcriptome and identify several thousand ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs).
View Article and Find Full Text PDFT-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose.
View Article and Find Full Text PDF